X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7485) 7485
Book Review (926) 926
Publication (453) 453
Conference Proceeding (22) 22
Book Chapter (20) 20
Dissertation (3) 3
Magazine Article (3) 3
Book / eBook (1) 1
Data Set (1) 1
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6953) 6953
humans (6438) 6438
camptothecin - analogs & derivatives (6109) 6109
camptothecin - administration & dosage (4941) 4941
female (3868) 3868
oncology (3755) 3755
male (3697) 3697
antineoplastic combined chemotherapy protocols - therapeutic use (3312) 3312
middle aged (3077) 3077
aged (2901) 2901
adult (2376) 2376
irinotecan (2336) 2336
chemotherapy (2195) 2195
cancer (1936) 1936
colorectal neoplasms - drug therapy (1781) 1781
fluorouracil - administration & dosage (1775) 1775
treatment outcome (1669) 1669
animals (1643) 1643
camptothecin (1495) 1495
camptothecin - adverse effects (1456) 1456
camptothecin - therapeutic use (1391) 1391
pharmacology & pharmacy (1360) 1360
antineoplastic combined chemotherapy protocols - adverse effects (1270) 1270
leucovorin - administration & dosage (1205) 1205
colorectal neoplasms - pathology (1187) 1187
organoplatinum compounds - administration & dosage (1146) 1146
colorectal cancer (1137) 1137
drug administration schedule (1091) 1091
mice (1079) 1079
antineoplastic agents, phytogenic - administration & dosage (1074) 1074
antineoplastic combined chemotherapy protocols - administration & dosage (1060) 1060
camptothecin - pharmacology (946) 946
camptothecin - pharmacokinetics (886) 886
fluorouracil (853) 853
cpt-11 (827) 827
cisplatin - administration & dosage (805) 805
oxaliplatin (770) 770
cell line, tumor (758) 758
antineoplastic agents - administration & dosage (755) 755
lung neoplasms - drug therapy (742) 742
disease-free survival (740) 740
aged, 80 and over (739) 739
dose-response relationship, drug (698) 698
survival rate (694) 694
bevacizumab (684) 684
care and treatment (682) 682
adenocarcinoma - drug therapy (678) 678
leucovorin (659) 659
liver neoplasms - secondary (638) 638
neoplasm staging (635) 635
deoxycytidine - analogs & derivatives (634) 634
medicine & public health (611) 611
antineoplastic agents - therapeutic use (602) 602
therapy (599) 599
metastasis (595) 595
neoplasm metastasis (595) 595
trial (589) 589
tumors (583) 583
neoplasms - drug therapy (578) 578
cisplatin (571) 571
5-fluorouracil (560) 560
analysis (547) 547
antineoplastic agents, phytogenic - therapeutic use (545) 545
pharmacokinetics (545) 545
research (539) 539
liver neoplasms - drug therapy (532) 532
antineoplastic agents (525) 525
deoxycytidine - administration & dosage (523) 523
survival analysis (522) 522
retrospective studies (521) 521
combination (518) 518
cetuximab (508) 508
infusions, intravenous (502) 502
camptothecin - chemistry (494) 494
phase-ii (487) 487
antimitotic agents (484) 484
topotecan (484) 484
antibodies, monoclonal - administration & dosage (480) 480
carcinoma (479) 479
1st-line treatment (468) 468
prognosis (461) 461
antibodies, monoclonal, humanized (458) 458
fluorouracil - therapeutic use (456) 456
fluorouracil - adverse effects (452) 452
drug therapy (447) 447
combined modality therapy (446) 446
colorectal neoplasms - mortality (441) 441
drug delivery systems (434) 434
survival (433) 433
antineoplastic agents, phytogenic - pharmacokinetics (430) 430
capecitabine (428) 428
antineoplastic agents - pharmacology (414) 414
surgery (414) 414
antineoplastic agents, phytogenic - adverse effects (413) 413
mice, nude (413) 413
drugs (411) 411
stomach neoplasms - drug therapy (411) 411
toxicity (408) 408
metastatic colorectal-cancer (401) 401
topoisomerase i inhibitors (392) 392
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6666) 6666
Japanese (606) 606
Chinese (85) 85
French (49) 49
German (32) 32
Italian (21) 21
Hungarian (12) 12
Russian (12) 12
Spanish (7) 7
Lithuanian (3) 3
Czech (2) 2
Korean (2) 2
Danish (1) 1
Norwegian (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 499 - 508
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 12/2014, Volume 477, Issue 1-2, pp. 399 - 407
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2009, Volume 20, Issue 11, pp. 1842 - 1847
Background: Bevacizumab significantly improves survival when added to chemotherapy for metastatic colorectal cancer (mCRC). The Bevacizumab Expanded Access... 
Expanded access study | Chemotherapy | First line | mCRC | Metastatic colorectal cancer | Bevacizumab | expanded access study | LEUCOVORIN | PHASE-II | first line | OXALIPLATIN | FLUOROURACIL | COMBINATION | chemotherapy | TRIAL | THERAPY | ONCOLOGY | bevacizumab | metastatic colorectal cancer | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Young Adult | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Deoxycytidine - adverse effects | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 31, pp. 3520 - 3526
Journal Article
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 03/2019, Volume 136, pp. 174 - 183
Hydrogels are widely studied as drug delivery system. In this work we propose the employment of tetrakis(hydroxymethyl)phosphonium chloride as crosslinking... 
Camptothecin | Chemotherapy | Drug delivery | Hydrogel | Mucoadhesivity | Oral administration | VITRO | RAT | PERMEABILITY ESTIMATION | CONTROLLED-RELEASE | MECHANISMS | GLUTARALDEHYDE | TRANSPORT | PHARMACOLOGY & PHARMACY | SINGLE-PASS VS | ABSORPTION | IN-SITU | Camptothecin - chemistry | Hydrogel, Polyethylene Glycol Dimethacrylate - chemistry | Rats, Wistar | Humans | Drug Carriers - administration & dosage | Male | Drug Carriers - chemistry | Dose-Response Relationship, Drug | Antineoplastic Agents, Phytogenic - administration & dosage | Hydrogel, Polyethylene Glycol Dimethacrylate - administration & dosage | Camptothecin - administration & dosage | Antineoplastic Agents, Phytogenic - pharmacokinetics | Cross-Linking Reagents - pharmacokinetics | Caco-2 Cells | Camptothecin - pharmacokinetics | Cross-Linking Reagents - chemistry | Administration, Oral | Chitosan - administration & dosage | Rats | Antineoplastic Agents, Phytogenic - chemistry | Hydrogel, Polyethylene Glycol Dimethacrylate - pharmacokinetics | Organophosphorus Compounds - chemistry | Cross-Linking Reagents - administration & dosage | Animals | Chitosan - chemistry | Chitosan - pharmacokinetics | Drug Carriers - pharmacokinetics | Organophosphorus Compounds - administration & dosage | Drug Delivery Systems - methods | Organophosphorus Compounds - pharmacokinetics | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 02/2012, Volume 72, Issue 3, pp. 779 - 789
The protein kinase BRAF is a key component of the RAS-RAF signaling pathway which plays an important role in regulating cell proliferation, differentiation,... 
XENOGRAFT MODELS | MELANOMA | PIK3CA GENE | ONCOLOGY | CETUXIMAB PLUS IRINOTECAN | IN-VIVO | WILD-TYPE BRAF | THYROID-CARCINOMA CELLS | B-RAF | KINASE INHIBITOR | RAF/MEK/ERK PATHWAY | Erlotinib Hydrochloride | Area Under Curve | Capecitabine | Colorectal Neoplasms - genetics | Humans | Indoles - administration & dosage | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Indoles - pharmacology | Quinazolines - administration & dosage | Phosphorylation - drug effects | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Camptothecin - analogs & derivatives | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | HCT116 Cells | Kaplan-Meier Estimate | Sulfonamides - pharmacology | Blotting, Western | Sulfonamides - pharmacokinetics | HT29 Cells | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Indoles - pharmacokinetics | Cell Proliferation - drug effects | Mice | Mutation | Colorectal Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | Mitogen-Activated Protein Kinases - metabolism | Index Medicus
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4706 - 4713
Panitumumab is a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in... 
SURVIVAL | 1ST-LINE TREATMENT | CONTROLLED-TRIAL | SUPPORTIVE CARE | ONCOLOGY | CETUXIMAB PLUS IRINOTECAN | KRAS | OXALIPLATIN | FAILURE | CHEMOTHERAPY | Leucovorin - administration & dosage | Predictive Value of Tests | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Chemotherapy, Adjuvant | Colorectal Neoplasms - metabolism | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Neoplasm Staging | Index Medicus
Journal Article
British Journal of Cancer, ISSN 0007-0920, 06/2017, Volume 117, Issue 1, pp. 33 - 40
Background: Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction between programmed cell death protein 1 (PD-1) on T-cells and PD-L1 and... 
clinical trial | pembrolizumab | advanced/metastatic solid tumours | phase I | chemotherapy | immunotherapy | CRITERIA | EFFICACY | CELL LUNG-CANCER | ONCOLOGY | ADVANCED MELANOMA | COHORT | NIVOLUMAB | IPILIMUMAB | Lung Neoplasms - drug therapy | Nausea - chemically induced | Humans | Middle Aged | Male | Fatigue - chemically induced | Vinblastine - administration & dosage | Diarrhea - chemically induced | Small Cell Lung Carcinoma - drug therapy | Pancreatic Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Vinblastine - analogs & derivatives | Doxorubicin - analogs & derivatives | Adult | Camptothecin - administration & dosage | Female | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Drug Eruptions - etiology | Deoxycytidine - administration & dosage | Albumins - administration & dosage | Treatment Outcome | Sarcoma - drug therapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Polyethylene Glycols - administration & dosage | Neoplasms - drug therapy | Taxoids - administration & dosage | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Gemcitabine | PD-1 protein | Toxicity | Exanthema | Diarrhea | Fatigue | Nausea | Lymphocytes T | Patients | Doxorubicin | Metastases | Irinotecan | Chemotherapy | Vomiting | Cell death | Immunotherapy | PD-L1 protein | Paclitaxel | Safety | Vinorelbine | Tumors | Cancer | Apoptosis | Index Medicus | metastatic solid tumours | advanced | Clinical Study
Journal Article